Cite
HARVARD Citation
Sada, M. et al. (2021). Ruxolitinib inhibits poly(I:C) and type 2 cytokines‐induced CCL5 production in bronchial epithelial cells: A potential therapeutic agent for severe eosinophilic asthma. Immunity, inflammation and disease. 9 (2), pp. 363-373. [Online].